Array comparative genomic hybridization analysis discloses chromosome copy number alterations as indicators of patient outcome in lymph node-negative breast cancer
Authors:
- Ryoko Kikuchi-KoikeRKRyoko Kikuchi-Koike
- Kazunori NagasakaKazunori Nagasaka
- Hitoshi TsudaHTHitoshi Tsuda
- Yasuyuki IshiiYIYasuyuki Ishii
- Masaru SakamotoMasaru Sakamoto
- Yoshihiro KikuchiYKYoshihiro Kikuchi
- Shiho FukuiSFShiho Fukui
- Yuko MiyagawaYMYuko Miyagawa
- Haruko HiraikeHHHaruko Hiraike
- Takayuki KobayashiTKTakayuki Kobayashi
- Takayuki KinoshitaTKTakayuki Kinoshita
- Yae KanaiYKYae Kanai
Open Access
- 30 May 2019
- journal article
- research article
- Published by Springer Nature in BMC Cancer
- Vol. 19 (1) , 521
Abstract
Patients with lymph node metastasis-negative (pN0) invasive breast cancer have favorable outcomes following initial treatment. However, false negatives which occur during routine histologic examination of lymph nodes are reported to underestimate the clinical stage of disease. To identify a high-risk group in pN0 invasive breast cancer, we examined copy number alterations (CNAs) of 800 cancer-related genes. Using array-based comparative genomic hybridization (CGH) in 51 pN0 cases (19 relapsed and 32 non-relapsed cases), the positivities of specific gene CNAs in the relapsed and non-relapsed groups were compared. An unsupervised hierarchical cluster analysis was then performed to identify case groups that were correlated with patient outcomes. The cluster analysis identified three distinct clusters of cases: groups 1, 2, and 3. The major component was triple-negative cases (69%, 9 of 13) in group 1, luminal B-like (57%, 13 of 23) and HER2-overexpressing (26%, 6 of 23) subtypes in group 2, and luminal A-like subtype (60%, 9 of 15) in group 3. Among all 51 cases, those in group 1 showed significantly worse overall survival (OS) than group 2 (p = 0.014), and 5q15 loss was correlated with worse OS (p = 0.017). Among 19 relapsed cases, both OS and relapse-free survival (RFS) rates were significantly lower in group 1 than in group 2 (p = 0.0083 and 0.0018, respectively), and 5q15 loss, 12p13.31 gain, and absence of 16p13.3 gain were significantly correlated with worse OS and RFS (p = 0.019 and 0.0027, respectively). As the target genes in these loci, NR2F1 (5q15), TNFRSF1A (12p13.31), and ABCA3 (16p13.3) were examined. 5q15 loss, 12p13.31 gain, and absence of 16q13.3 gain were potential indicators of high-risk recurrence and aggressive clinical behavior of pN0 invasive breast cancers.Keywords
This publication has 36 references indexed in Scilit:
- Global Cancer in Women: Burden and TrendsCancer Epidemiology, Biomarkers & Prevention, 2017
- Tailoring therapies—improving the management of early breast cancer: St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2015Annals of Oncology, 2015
- Personalizing the treatment of women with early breast cancer: highlights of the St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2013Annals of Oncology, 2013
- Ki67 Index, HER2 Status, and Prognosis of Patients With Luminal B Breast CancerJNCI: Journal of the National Cancer Institute, 2009
- Oral Uracil and Tegafur Compared With Classic Cyclophosphamide, Methotrexate, Fluorouracil As Postoperative Chemotherapy in Patients With Node-Negative, High-Risk Breast Cancer: National Surgical Adjuvant Study for Breast Cancer 01 TrialJournal of Clinical Oncology, 2009
- The molecular portraits of breast tumors are conserved across microarray platformsBMC Genomics, 2006
- Immunohistochemical and Clinical Characterization of the Basal-Like Subtype of Invasive Breast CarcinomaClinical Cancer Research, 2004
- A Gene-Expression Signature as a Predictor of Survival in Breast CancerNew England Journal of Medicine, 2002
- Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implicationsProceedings of the National Academy of Sciences of the United States of America, 2001
- Molecular portraits of human breast tumoursNature, 2000